-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, LO2N2gyHHMYaVBzwmu23Hy4jEQ6kLCO8wiatelUiDrxat/Kj+7GOG4PtRsNZnbgP RsYJi37ut4UbfDong2Idkg== 0000950144-01-002504.txt : 20010223 0000950144-01-002504.hdr.sgml : 20010223 ACCESSION NUMBER: 0000950144-01-002504 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20010214 GROUP MEMBERS: QFINANCE INC GROUP MEMBERS: QUINTILES TRANSNATIONAL CORP SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CV THERAPEUTICS INC CENTRAL INDEX KEY: 0000921506 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 431570294 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: SEC FILE NUMBER: 005-47551 FILM NUMBER: 1539549 BUSINESS ADDRESS: STREET 1: 3172 PORTER DR CITY: PALO ALTO STATE: CA ZIP: 94304 BUSINESS PHONE: 6508120585 MAIL ADDRESS: STREET 1: 3172 PORTER DRIVE CITY: PALO ALTO STATE: CA ZIP: 94304 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: QUINTILES TRANSNATIONAL CORP CENTRAL INDEX KEY: 0000919623 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 561714315 STATE OF INCORPORATION: NC FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 4709 CREEKSTONE DR STREET 2: RIVERBIRCH BLDG STE 200 CITY: DURHAM STATE: NC ZIP: 27703-8411 BUSINESS PHONE: 9199982000 MAIL ADDRESS: STREET 1: 4709 CREEKSTONE DR STREET 2: STE 300 CITY: DURHAM STATE: NC ZIP: 27703-8411 SC 13G/A 1 g66926asc13ga.txt CV THERAPEUTICS/QUINTILES TRANSNATIONAL 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) * CV THERAPEUTICS, INC. --------------------- (Name of Issuer) COMMON STOCK, $.001 PAR VALUE PER SHARE --------------------------------------- (Title of Class of Securities) 126667 10 4 -------------- (CUSIP Number) DECEMBER 1, 2000 ------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [X] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). (Continued on following page(s)) Page 1 of 8 Pages 2
- ------------------------- ------------------------ CUSIP No. 126667 10 4 Schedule 13G Page 2 of 8 Pages - ------------------------- ------------------------ - ------------------------------------------------------------------------------------ 1) NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only). Quintiles Transnational Corp. I.R.S. Employer Identification No.: 56-1714315 - ------------------------------------------------------------------------------------ 2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) [ ] (b) [ ] Joint Filing - ------------------------------------------------------------------------------------ 3) SEC USE ONLY - ------------------------------------------------------------------------------------ 4) CITIZENSHIP OR PLACE OF ORGANIZATION North Carolina - ------------------------------------------------------------------------------------ 5) SOLE VOTING POWER NUMBER OF -0- SHARES --------------------------------------------------------- BENEFICIALLY 6) SHARED VOTING POWER OWNED BY 993,705(1) EACH --------------------------------------------------------- REPORTING 7) SOLE DISPOSITIVE POWER PERSON -0- WITH: --------------------------------------------------------- 8) SHARED DISPOSITIVE POWER 993,705(1) - ------------------------------------------------------------------------------------ 9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 993,705(1) - ------------------------------------------------------------------------------------ 10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) [ ] - ------------------------------------------------------------------------------------ 11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.09%(2) - ------------------------------------------------------------------------------------ 12) TYPE OF REPORTING PERSON (See Instructions) CO - ------------------------------------------------------------------------------------
(1) Includes 993,705 shares of common stock of CV Therapeutics, Inc. (the "Issuer"), par value $.001 per share, held by QFinance, Inc., a wholly-owned subsidiary of Quintiles Transnational Corp., which are reported by QFinance, Inc. on the following page. (2) Calculated based on 19,523,045 shares of outstanding Common Stock of the Issuer on December 31, 2000, as reported in the Issuer's Form S-3/A filing with the Securities and Exchange Commission on January 12, 2001. 3
- ------------------------- ------------------------ CUSIP No. 126667 10 4 Schedule 13G Page 3 of 8 Pages - ------------------------- ------------------------ - ------------------------------------------------------------------------------------ 1) NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only). QFinance, Inc. I.R.S. Employer Identification No.: 62-1784909 - ------------------------------------------------------------------------------------ 2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) [ ] (b) [ ] Joint Filing - ------------------------------------------------------------------------------------ 3) SEC USE ONLY - ------------------------------------------------------------------------------------ 4) CITIZENSHIP OR PLACE OF ORGANIZATION Delaware - ------------------------------------------------------------------------------------ 5) SOLE VOTING POWER NUMBER OF -0- SHARES --------------------------------------------------------- BENEFICIALLY 6) SHARED VOTING POWER OWNED BY 993,705 EACH --------------------------------------------------------- REPORTING 7) SOLE DISPOSITIVE POWER PERSON -0- WITH: --------------------------------------------------------- 8) SHARED DISPOSITIVE POWER 993,705 - ------------------------------------------------------------------------------------ 9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 993,705 - ------------------------------------------------------------------------------------ 10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) [ ] - ------------------------------------------------------------------------------------ 11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.09%(3) - ------------------------------------------------------------------------------------ 12) TYPE OF REPORTING PERSON (See Instructions) CO - ------------------------------------------------------------------------------------
(3) Calculated based on 19,523,045 shares of outstanding Common Stock of the Issuer on December 31, 2000, as reported in the Issuer's Form S-3/A filing with the Securities and Exchange Commission on January 12, 2001. 4 - ------------------------- -------------------- CUSIP No. 126667 10 4 Schedule 13G Page 4 of 8 Pages - ------------------------- -------------------- ITEM 1. (a) Name of Issuer CV Therapeutics, Inc. (b) Address of Issuer's Principal Executive Offices 3172 Porter Drive Palo Alto, California 94304 ITEM 2. (a) Name of Person Filing This statement is filed jointly on behalf of Quintiles Transnational Corp. ("Quintiles") and QFinance, Inc. ("QFinance"), a wholly-owned subsidiary of Quintiles, pursuant to Rule 13d-1(k)(1). (b) Address of Principal Business Office or, if none, Residence Quintiles' principal business office is at 4709 Creekstone Drive, Riverbirch Building, Suite 200, Durham, North Carolina 27703. QFinance's principal business office is c/o Quintiles Transnational Corp., 4709 Creekstone Drive, Riverbirch Building, Suite 200, Durham, North Carolina 27703. (c) Citizenship Quintiles is a North Carolina corporation. QFinance is a Delaware corporation. (d) Title of Class of Securities Common stock, par value $.001 per share (e) CUSIP Number 126667 10 4 ITEM 3. Not applicable. ITEM 4. Ownership (a) Amount Beneficially Owned: 993,705 shares. (b) Percent of Class: Such 993,705 shares of Common Stock are 5.09% of the 19,523,045 shares of Common Stock outstanding as of December 31, 2000, as reported by CV Therapeutics, Inc. in its S-3/A filed with the Securities and Exchange Commission on January 12, 2001. (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: -0- (ii) shared power to vote or to direct the vote: 993,705 (iii) sole power to dispose or to direct the disposition of: -0- (iv) shared power to dispose or to direct the disposition of: 993,705 5 - ------------------------- -------------------- CUSIP No. 126667 10 4 Schedule 13G Page 5 of 8 Pages - ------------------------- -------------------- ITEM 5. Ownership of Five Percent or Less of a Class Not applicable. ITEM 6. Ownership of More than Five Percent on Behalf of Another Person Not applicable. ITEM 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company Not applicable. ITEM 8. Identification and Classification of Members of the Group Not applicable. ITEM 9. Notice of Dissolution of Group Not applicable. ITEM 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 14, 2001 QUINTILES TRANSNATIONAL CORP. By: /s/ James L. Bierman ----------------------------- Name: James L. Bierman Title: Chief Financial Officer QFINANCE, INC. By: /s/ Thomas Perkins ----------------------------- Name: Thomas Perkins Title: President 6 - ------------------------- -------------------- CUSIP No. 126667 10 4 Schedule 13G Page 6 of 8 Pages - ------------------------- -------------------- EXHIBIT INDEX Exhibit Number Description 1 Joint Filing Agreement between Quintiles Transnational Corp. and QFinance, Inc. EX-99.1 2 g66926aex99-1.txt JOINT FILING AGREEMENT 1 - ------------------------- -------------------- CUSIP No. 126667 10 4 Schedule 13G Page 7 of 8 Pages - ------------------------- -------------------- Exhibit 1 Joint Filing Agreement (Attached) 2 - ------------------------- -------------------- CUSIP No. 126667 10 4 Schedule 13G Page 8 of 8 Pages - ------------------------- -------------------- JOINT FILING AGREEMENT Each of the undersigned hereby agrees and consents that the Schedule 13G filed herewith (the "Schedule 13G") by Quintiles Transnational Corp. ("Quintiles") is filed on behalf of each of them pursuant to the authorization of the undersigned to Quintiles to make such filing and that such Schedule 13G is filed jointly on behalf of each of them, pursuant to Sections 13(d) and 13(g) of the Securities Exchange Act of 1934, as amended, and the rules promulgated thereunder, including Rule 13d-1(k)(l). Each of the undersigned hereby agrees that such Schedule 13G is, and any further amendments to the Schedule 13G will be, filed on behalf of each of the undersigned. Each of the persons is not responsible for the completeness or accuracy of the information concerning the other persons making this filing unless such person knows or has reason to believe that such information is inaccurate. This agreement may be signed in counterparts. This agreement is effective as of February 14, 2001. QUINTILES TRANSNATIONAL CORP. By: /s/ James L. Bierman --------------------------------- Name: James L. Bierman Title: Chief Financial Officer QFINANCE, INC. By: /s/ Thomas Perkins --------------------------------- Name: Thomas Perkins Title: President -----END PRIVACY-ENHANCED MESSAGE-----